NO995776D0 - Fremgangsmåte for behandling av trombosesykdommer - Google Patents

Fremgangsmåte for behandling av trombosesykdommer

Info

Publication number
NO995776D0
NO995776D0 NO995776A NO995776A NO995776D0 NO 995776 D0 NO995776 D0 NO 995776D0 NO 995776 A NO995776 A NO 995776A NO 995776 A NO995776 A NO 995776A NO 995776 D0 NO995776 D0 NO 995776D0
Authority
NO
Norway
Prior art keywords
treatment
thrombosis
combination therapy
result
limited
Prior art date
Application number
NO995776A
Other languages
English (en)
Other versions
NO995776L (no
Inventor
Brian William Grinnell
Joseph Anthony Jakubowski
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO995776D0 publication Critical patent/NO995776D0/no
Publication of NO995776L publication Critical patent/NO995776L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4866—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • External Artificial Organs (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
NO995776A 1997-06-05 1999-11-25 Fremgangsmåte for behandling av thrombosesykdommer NO995776L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4862897P 1997-06-05 1997-06-05
PCT/US1998/011071 WO1998055142A1 (en) 1997-06-05 1998-06-01 Methods for treating thrombotic disorders

Publications (2)

Publication Number Publication Date
NO995776D0 true NO995776D0 (no) 1999-11-25
NO995776L NO995776L (no) 2000-01-26

Family

ID=21955575

Family Applications (1)

Application Number Title Priority Date Filing Date
NO995776A NO995776L (no) 1997-06-05 1999-11-25 Fremgangsmåte for behandling av thrombosesykdommer

Country Status (23)

Country Link
US (1) US6071514A (no)
EP (1) EP0882453B1 (no)
JP (1) JP2002502421A (no)
KR (1) KR20010013413A (no)
CN (2) CN1265598A (no)
AT (1) ATE286404T1 (no)
AU (1) AU741983B2 (no)
BR (1) BR9809932A (no)
CA (1) CA2293429A1 (no)
DE (1) DE69828462T2 (no)
DK (1) DK0882453T3 (no)
EA (1) EA199901112A1 (no)
ES (1) ES2235291T3 (no)
HU (1) HUP0003964A2 (no)
ID (1) ID23908A (no)
NO (1) NO995776L (no)
PL (1) PL337223A1 (no)
PT (1) PT882453E (no)
SI (1) SI0882453T1 (no)
TR (1) TR199903020T2 (no)
TW (1) TWI228042B (no)
WO (1) WO1998055142A1 (no)
ZA (1) ZA984698B (no)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19781869T1 (de) * 1996-04-30 2000-03-16 Medtronic Inc Verfahren zur Herstellung eines autologen Fibrin-Blutstillungsmittels
WO2000062828A1 (en) * 1996-04-30 2000-10-26 Medtronic, Inc. Autologous fibrin sealant and method for making the same
US6693075B1 (en) * 1997-10-23 2004-02-17 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6747003B1 (en) * 1997-10-23 2004-06-08 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7247708B2 (en) * 1997-10-23 2007-07-24 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6953568B1 (en) 1998-08-25 2005-10-11 Oklahoma Medical Research Foundation Targeting of molecules to large vessel endothelium using EPCR
EP1093814A1 (en) * 1999-10-22 2001-04-25 Boehringer Ingelheim Pharma KG Use of dipyridamole or mopidamol in the manufacture of a medicament for the treatment and prevention of fibrin-dependent microcirculation disorders
DE60144366D1 (de) * 2000-02-04 2011-05-19 Scripps Research Inst Neuroprotektive, antithrombotische und anti-entzündliche anwendungen von aktiviertem protein c
US7812132B2 (en) 2000-04-28 2010-10-12 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US20030056244A1 (en) * 2000-05-02 2003-03-20 Ning Huang Feed additive compositions and methods
US20030211094A1 (en) * 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
US8906894B1 (en) 2000-07-27 2014-12-09 Thomas N. Thomas Methods for preventing and treating thrombotic disorders
AU2002213192A1 (en) * 2000-10-13 2002-04-22 The Trustees Of Columbia University In The City Of New York A method for inhibiting new tissue growth in blood vessels in a patient subjected to blood vessel injury
US6942880B1 (en) * 2001-04-09 2005-09-13 Medtronic, Inc. Autologous platelet gel having beneficial geometric shapes and methods of making the same
US7064130B2 (en) * 2001-04-20 2006-06-20 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of radical-scavenging compounds for treatment and prevention of NO-dependent microcirculation disorders
US20030073636A1 (en) * 2001-09-19 2003-04-17 Oklahoma Medical Research Foundation Method of treating diabetes
EP1453529A4 (en) * 2001-09-19 2007-09-26 Oklahoma Med Res Found TREATMENT OF SEPSIS WITH TAFI
RU2322984C2 (ru) 2001-10-05 2008-04-27 Комбинаторкс, Инкорпорейтед Комбинации для лечения иммуновоспалительных расстройств
RU2357974C2 (ru) 2003-01-10 2009-06-10 Аблинкс Н.В. Терапевтические полипептиды, их гомологи, их фрагменты и их применение для модуляции агрегации, опосредованной тромбоцитами
US20070142272A1 (en) * 2003-01-24 2007-06-21 Zlokovic Berislav V Neuroprotective activity of activated protein c independent of its anticoagulant activity
TW200517114A (en) 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
WO2006014839A2 (en) * 2004-07-23 2006-02-09 The University Of Rochester Activated protein c inhibits undesirable effects of plasminogen activator in the brain
PL2007362T3 (pl) * 2006-04-04 2019-02-28 Kg Acquisition Llc Doustne postacie leku obejmujące czynnik przeciwpłytkowy i inhibitor kwasu
US9096839B2 (en) * 2006-04-26 2015-08-04 Arteriocyte Medical Systems, Inc. Compositions and methods of preparation thereof
CA2652773A1 (en) * 2006-05-22 2007-12-06 Combinatorx, Incorporated Methods and compositions for the treatment of diseases or conditions associated with increased c-reactive protein, interleukin-6, or interferon-gamma levels
EP2152078B8 (en) 2007-04-27 2021-03-17 CyDex Pharmaceuticals, Inc. Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use
CA2737131A1 (en) * 2007-09-19 2009-03-26 Zalicus Inc. Therapeutic regimens for the treatment of immunoinflammatory disorders
JP2011506607A (ja) * 2007-12-17 2011-03-03 ザリカス インコーポレイティッド 免疫炎症性障害の処置のための治療法
DE102007063234A1 (de) * 2007-12-31 2009-07-02 Nowak, Attila, Dipl.-Ing. Schnellere Speicherorganisation
US20100280594A1 (en) * 2009-05-01 2010-11-04 Medi-Solve, Llc Antithrombotic Neurovascular Device Containing a Glycoprotein IIB/IIIA Receptor Inhibitor for The Treatment of Brain Aneurysms and/or Acute Ischemic Stroke, and Methods Related Thereto
US8236782B2 (en) 2009-05-13 2012-08-07 Cydex Pharmaceuticals, Inc. Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same
CN108159399B (zh) * 2017-12-29 2020-07-24 华中科技大学同济医学院附属同济医院 一种凝血蛋白酶aPC在防治糖尿病心肌病药物中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775624A (en) * 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
US5516650A (en) * 1985-06-27 1996-05-14 Zymogenetics, Inc. Production of activated protein C
US5084274A (en) * 1987-11-17 1992-01-28 Scripps Clinic And Research Foundation Inhibition of arterial thrombotic occlusion or thromboembolism
US4992373A (en) * 1987-12-04 1991-02-12 Eli Lilly And Company Vectors and compounds for direct expression of activated human protein C
JP2739050B2 (ja) * 1988-01-28 1998-04-08 ヘキスト薬品工業株式会社 抗血液凝固剤
US4981952A (en) * 1988-10-04 1991-01-01 Eli Lilly And Company Method for the purification of vitamin K-dependent proteins
IL97312A (en) * 1990-02-23 1999-01-26 Lilly Co Eli A method of generating a polypeptide in an eukaryotic vector AND recombinant surrogate cell containing an enhanced transcriptional control unit based on the primary late adenovirus coefficient
FR2671973A1 (fr) * 1991-01-25 1992-07-31 Fondation Nale Transfusion San Utilisation de la proteine c activee comme agent anti-agregant plaquettaire.
WO1993009807A1 (en) * 1991-11-18 1993-05-27 The Scripps Research Institute Methods of inhibiting thrombosis via elevation of circulating endogenous activated protein c levels
JPH05271098A (ja) * 1992-03-26 1993-10-19 Teijin Ltd 活性化プロテインｃを有効成分とする抗血小板剤
MY110664A (en) * 1992-05-21 1999-01-30 Lilly Co Eli Protein c derivatives
IL110172A (en) * 1993-07-22 2001-10-31 Lilly Co Eli Bicycle compounds and pharmaceuticals containing them
WO1997020043A1 (en) * 1995-11-30 1997-06-05 Zymogenetics, Inc. Protein c production in transgenic animals

Also Published As

Publication number Publication date
ATE286404T1 (de) 2005-01-15
CN1265598A (zh) 2000-09-06
EP0882453A3 (en) 2001-04-04
JP2002502421A (ja) 2002-01-22
AU7710098A (en) 1998-12-21
EP0882453B1 (en) 2005-01-05
DE69828462D1 (de) 2005-02-10
DE69828462T2 (de) 2005-12-15
ZA984698B (en) 2000-02-01
TR199903020T2 (xx) 2000-08-21
KR20010013413A (ko) 2001-02-26
NO995776L (no) 2000-01-26
PL337223A1 (en) 2000-08-14
BR9809932A (pt) 2000-08-01
WO1998055142A1 (en) 1998-12-10
CN1347734A (zh) 2002-05-08
ID23908A (id) 2000-05-25
AU741983B2 (en) 2001-12-13
US6071514A (en) 2000-06-06
HUP0003964A2 (en) 2001-03-28
EP0882453A2 (en) 1998-12-09
TWI228042B (en) 2005-02-21
EA199901112A1 (ru) 2000-06-26
PT882453E (pt) 2005-04-29
SI0882453T1 (en) 2005-06-30
DK0882453T3 (da) 2005-05-09
CA2293429A1 (en) 1998-12-10
ES2235291T3 (es) 2005-07-01

Similar Documents

Publication Publication Date Title
NO995776D0 (no) Fremgangsmåte for behandling av trombosesykdommer
BR0212039B1 (pt) dispositivo terapêutico a laser de nìvel baixo.
IL143870A0 (en) Method of using a cyclooxygenase-2 inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
EA200300953A1 (ru) Терапевтические комбинации для применения при сердечно-сосудистых и воспалительных заболеваниях
BR0107230A (pt) Método de tratamento superficial de implantes ou próteses feitos em titânio ou outros materiais
NO920946L (no) Oral antikoagulant/blodplateinhibitor i lavdoseformulering
DE69805973T2 (de) Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin-abhängigen protein kinase
NO993396L (no) Kinolin- og kinolinforbindelser nyttige i terapi, spesielt i behandlingen av benign prostatisk hyperplasi
NO20013064D0 (no) Kombinasjonsterapi med bestråling og en cox-2-inhibitor ved behandling av neoplasia
ZA943896B (en) Pharmaceutical agents for treatment of emesis
EE200300364A (et) 3,7-diasabitsüklo[3,3,0]oktaanid ja nende kasutamine südame arütmiate ravis
HK1037980A1 (en) Use of selegiline or desmethylselegiline for the manufacture of a medicament for treating wounds, burns or photodamage.
DE60037032D1 (de) Anwendung von pdt zur inhibierung von hyperplasie der intima
HUP0002836A2 (hu) Makrociklusos bisz(3,3'-indolil)-maleinimid-származékok alkalmazása bőrrendellenességek kezelésére szolgáló gyógyszerkészítmények előállítására
DE69939075D1 (de) Pharmazeutische Zusammenstellung zur Vorbeugung und Behandlung von mit Zellkrankheiten des Augenhintergrundes zusammenhängenden Krankheiten
CA2297984A1 (en) Ratite extracts as therapeutic agents
DK664188D0 (da) Butylhydroxyanisoler til behandling af retrovirale sygdomme
DK0661058T3 (da) Anvendelse af bradykininantagonister til behandling af virussygdomme
DK0836853T3 (da) Anvendelse af bradykinin-antagonister til fremstilling af lægemidler til behandling og forebyggelse af Alzheimers sygdom
IT1276321B1 (it) Derivati del carbossimetilidenecicloptimmidazolo procedimento di fabbricazione dei derivati e agenti terapeutici che contengono
ATE314073T1 (de) Kombination von aktiva mit alfuzosin und apomorphin
ITVR920053V0 (it) Vaporizzatore comprendente organi per il dosaggio, la diffusione e la vaporizzazione dell'acqua applicabile preferibilmente su forni modula-ri o similari
CA2027593A1 (fr) Composition a activite anti-agregante plaquettaire utilisable en therapeutique
ATE94759T1 (de) Verwendung von dextransulfat, gegebenenfalls in kombination mit anti-androgenen mitteln zur behandlung des humanen protatakarzinoms.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application